<DOC>
	<DOCNO>NCT02966548</DOCNO>
	<brief_summary>This study use determine safety tolerability BMS-986016 administer alone combination Nivolumab subject advanced solid tumor .</brief_summary>
	<brief_title>Safety Study BMS-986016 With Without Nivolumab Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Must histologic cytologic confirmation incurable solid malignancy advance ( metastatic and/or unresectable ) Must receive , progress intolerant , standard treatment regimen advance metastatic setting , therapy exists Presence least one lesion measurable disease define RECIST v1.1 criterion response assessment Males Females , age 20 year old , inclusive Known suspect CNS ( central nervous system ) metastases CNS site active disease Other concomitant malignancy ( exception per protocol ) Any active autoimmune disease history know suspect autoimmune disease History uncontrolled significant cardiovascular disease Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>